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9 Abstract
10 Purpose of Review The role of bone-derived factors in regu-
11 lation of skeletal muscle function is an important emerging
12 aspect of research into bone-muscle crosstalk. Implications
13 for this area of research are far reaching and include under-
14 standing skeletal muscle weakness in cancer, osteoporosis,
15 cachexia, rare diseases of bone, and aging.
16 Recent Findings Recent research shows that bone-derived fac-
17 tors can lead to changes in the skeletal muscle. These changes
18 can either be anabolic or catabolic, and we focus this review on
19 the role of TGFβ in driving oxidative stress and skeletal muscle
20 weakness in the setting of osteolytic cancer in the bone.
21 Summary The bone is a preferred site for breast cancer me-
22 tastasis and leads to pathological bone loss. Osteolytic cancer
23 in the bone leads to release of TGFβ from the bone via
24 osteoclast-mediated bone destruction. Our appreciation of
25 crosstalk between the muscle and bone has recently expanded
26 beyond mechanical force-driven events to encompass a vari-
27 ety of signaling factors originating in one tissue and commu-
28 nicating to the other. This review summarizes some previously
29 known mediators of bone-to-muscle signaling and also recent
30 work identifying a new role for bone-derived TGFβ as a cause
31 of skeletal muscle weakness in the setting of osteolytic cancer
32 in the bone. Multiple points of potential therapeutic interven-
33 tion are discussed.
34Keywords Bone . Skeletal muscle . TGFβ . Bone-muscle
35crosstalk
36Introduction
37Our understanding of bone-muscle crosstalk has been histor-
38ically based on mechanical interactions between the bone and
39muscle. The bone is shaped by mechanical force applied by
40muscles, and the bone provides an attachment site for the
41muscle to maintain shape and drive locomotion. The mechan-
42ical aspects of bone-muscle interactions are critical for normal
43development and movement and play a large role in changes
44of these tissues in disease and aging, yet the interactions be-
45tween the bone and muscle are more complicated. Just as our
46understanding of other organ system integrations has ad-
47vanced, so too has our understanding of the complex
48endocrine-based crosstalk between the bone and muscle.
49Bone and muscle anabolism are tightly coupled during growth
50and development. Conversely, bone and muscle catabolism
51occur during aging. Compromising either the bone or muscle
52by disease, disuse or aging affects both tissues but the cellular
53and molecular mechanisms linking these are not well under-
54stood. It is in this context that we describe the role of
55transforming growth factor beta (TGFβ) in bone-muscle
56crosstalk and muscle weakness that occurs in osteolytic cancer
57in bone.
Bone 58 -to-Skeletal-Muscle Signaling
59The bone is a storehouse for minerals, collagenous, and non-
60collagenous proteins; the latter of which includes growth fac-
61tors and cytokines [1]. The bone also acts as an active signal-
62ing mediator and endocrine organ [2, 3]. In addition,
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63 osteoblasts and osteocytes in the bone secrete paracrine and
64 endocrine factors that can influence the skeletal muscle. The
65 consequences of bone-to-muscle signaling include changes in
66 skeletal muscle mass and changes in skeletal muscle function
67 [4].
68 Many of these bone-derived growth factors may have sig-
69 nificant effects on muscle function. Osteocalcin is secreted by
70 osteoblasts and signals via the G protein-coupled receptor,
71 Gprc6a, in many cell types including the skeletal muscle. In
72 humans, the level of active osteocalcin correlates with an in-
73 crease in lower limb strength [5•]. Osteocalcin production is
74 increased in response to insulin signaling in osteoblasts.
75 Circulating osteocalcin then promotes a feed-forward loop
76 by increasing insulin synthesis and increasing insulin sensitiv-
77 ity in adipose tissue and muscle [6, 7]. Additionally,
78 osteocalcin signaling in the skeletal muscle increases mito-
79 chondrial content [8]. Interestingly, skeletal muscle mass, fi-
80 ber number, abundance of contractile proteins, and specific
81 force (i.e., normalized for size and weight of the muscle) were
82 impacted using a bone-targeted connexin 43 in mice [9].
83 Osteocalcin levels were reduced in the connexin-43 mice but
84 interestingly, insulin signaling was not affected. Using a syn-
85 thetic osteocalcin, some of the abnormalities in muscle were
86 rescued, suggesting that osteocalcin may have direct effects in
87 the skeletal muscle [9].
88 Insulin-like growth factor 1 (IGF1) and bone morphoge-
89 netic protein 2 (BMP2), produced by osteoblasts, can be
90 stored in the mineral bone matrix and released as a result of
91 osteoclast-medicated bone resorption [10]. IGF1 promotes
92 proliferation and differentiation of myogenic cells and is an
93 important regulator of muscle mass during development [11].
94 In adult skeletal muscle, Akt activation downstream of IGF1
95 signaling causes significant hypertrophy that showed in-
96 creased force but the specific force was unchanged [12].
97 BMP2 signaling in muscle has been shown to promote and
98 maintain adult muscle mass [13••, 14, 15]. Interestingly, this
99 model of growth factor signaling-induced hypertrophy also
100 increased absolute muscle force, yet specific force was un-
101 changed or even slightly decreased [13••].
102 Prostaglandin E2 (PGE2) is one of several factors released
103 by osteocytes. This release occurs in the bone by exposure to
104 fluid shear stress [16, 17]. PGE2 promotes osteocyte survival
105 [18] and induces new bone formation [19]. PGE2 also accel-
106 erates myogenic differentiation in vitro [20]. The significance
107 of PGE2 signaling in the skeletal muscle is not completely
108 understood and will require more studies [4].
109 In contrast to bone-derived factors leading to a hypertro-
110 phic response in the skeletal muscle, several osteokines are
111 associated with reduced muscle mass or function. Fibroblast
112 growth factor 23 (FGF-23) is produced in the bone by osteo-
113 cytes and is critical for proper mineral metabolism. FGF-23
114 neutralizing antibody, which increases serum phosphate and
115 1,25 dihydroxyvitamin D3 levels, has been shown to improve
116murine grip strength in a model of rickets/osteomalacia (X-
117linked hypohosphatemic rickets/osteomalacia [XLH]) [21,
11822]. In Dmp1 null mice, a model of autosomal recessive
119hypophosphatemic rickets, skeletal muscle function was re-
120duced (EDL and soleus muscles) but cardiac force production
121was not affected [23]. These data suggest that FGF-23, and in
122addition to vitamin D levels, could influence skeletal muscle
123function.
124TGFβ and its family members myostatin and activin cause
125muscle atrophy or lead to reduced function. TGFβ and activin
126are made by osteoblasts and stored in the mineralized bone
127matrix [24, 25•, 26]. Activin and TGFβ are released into cir-
128culation from the bone matrix during osteoclast-mediated
129bone resorption. Both TGFβ and activin can affect the muscle,
130but their mode of action differs. Activin strongly induces skel-
131etal muscle wasting in vivo using an adenovirus vector in
132mice. In these studies, there was a profound loss of skeletal
133muscle mass and decrease in peak force production yet no
134change in specific force [27]. In contrast, mice treated
135in vivo with TGFβ did not have altered muscle mass but did
136have a significant decrease in both raw force and specific force
137[28••].
138Bone-Derived TGFβ Causes Skeletal Muscle
139Weakness
140Cancer cells frequently metastasize to the bone, affecting
141some 450,000 patients in the USA each year. Osteolytic can-
142cer in the bone causes decreased quality of life and decreased
143survival in patients [29, 30]. Osteolytic cancer metastases in
144the bone from breast cancer increase the risk of pathologic
145fractures. This significantly increases mortality in patients
146compared to patients without fractures [30]. From a clinical
147perspective, systemic muscle weakness is either unrecognized
148or under-appreciated by many clinicians. Systemic muscle
149weakness increases the incidence of falls that result in frac-
150tures, and this can develop into a vicious feed-forward cycle of
151increased impact to functional performance which further in-
152fluences risk of falls and fractures. The end result is further
153eroded quality of life and decreased survival [4].
154Bone metastasis is a complex process which begins with
155the detachment of primary tumor cells from the site of origin
156and systemic circulation (intravasation). The tumor cells must
157evade immune surveillance and enter the capillaries in the
158bone marrow [31]. Micrometastases of tumor cells in the bone
159develop into either overt metastatic lesions or can lay dormant
160for extended periods. In either case, invading tumor cells can
161prime the bone pre-metastatic niche that allows for further
162colonization of tumor cells [32–35].
163In the normal adult setting, bone is constantly remodeled to
164adjust for functional demands or to repair microfractures that
165occur as a part of normal activity [4]. This process is driven by
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166 the coupled activity of osteoclasts that resorb mineralized ma-
167 trix and osteoblast that lay down new bone [36, 37]. Bone
168 strength is maintained in healthy adults by a coordinate bal-
169 ance of bone-destroying osteoclasts and bone-forming osteo-
170 blasts. Ultimately, tumor cells in the bone microenvironment
171 disrupt this normal physiological process. In the case of most
172 breast cancers metastatic to bone, the tumor cells produce
173 factors that directly or indirectly induce the formation of oste-
174 oclasts. In turn, bone resorption releases growth factors from
175 bone matrix (e.g., TGFβ) that stimulate tumor growth and
176 further osteolysis. This reciprocal interaction between breast
177 cancer cells and the bone microenvironment results in a “vi-
178 cious cycle” that increases both bone destruction and the tu-
179 mor burden [35].
180 TGFβ plays a central role in tumor growth in the bone
181 [38–41] and is released in high concentrations from the min-
182 eralized bonematrix during osteoclastic bone resorption [40•].
183 In addition, bone metastases are effectively decreased by
184 TGFβ signaling blockade [41]. Our recent work has shown
185 the novel idea that factors released from the bone during
186 tumor-induced bone destruction exert systemic musculoskel-
187 etal effects beyond the immediate bone microenvironment
188 (Fig. 1Q2 ). We have shown significant skeletal muscle weakness
189 in mice with osteolytic cancer in the bone, specifically in bone
190 metastases from either prostate, lung, or breast cancers and
191 also in multiple myeloma which affects the bone [42••].
192These changes in the muscle occur without direct involvement
193of tumor cells in the muscle. In addition, muscle weakness is
194not observed when breast cancer cells (MDA-MB-231) are
195restricted to the primary site (i.e., mammary fat pad without
196bone metastases). Muscle weakness became more prominent
197with increasing osteolytic lesion area in mice. Furthermore,
198we found that muscle weakness was systemic. Tumor cells
199injected directly into one tibia and that led to local osteolytic
200lesions that caused muscle weakness in the contralateral limb
201[42••].
202In our study, mice with osteolytic cancer in the bone had
203reduced grip strength in vivo (forelimb) and also decreased
204whole muscle contractility measured as the specific force of
205the extensor digitorum longus (EDL) muscle. The difference
206in specific force suggested a defect in the contractile machin-
207ery in muscle. An unbiased proteomics screen was used to
208identify myocyte proteins that were modified in mice with
209osteolytic cancer in the bone. We identified the ryanodine
210receptor (RyR1) as being oxidized in the skeletal muscle from
211these mice compared to muscle from non-tumor bearing con-
212trols. RyR1 oxidation and loss of its stabilizing subunit,
213calstabin1, are unique biochemical signatures of RyR1 chan-
214nel calcium leak that leads to muscle weakness [43, 44]. These
215biochemical signatures were present in the muscle from mice
216with osteolytic cancer in the bone and multiple myeloma, but
217not from mice with primary breast cancer. Also, the
Fig. 1 TGFβ and activin signal
from bone to muscle during
tumor-induced osteolytic bone
destruction. Upon resorption of the
mineralized bone matrix, active
TGFβ and activin are released into
circulation and act upon skeletal
muscle. Activin causes significant
reductions in muscle size while
TGFβ reduces muscle size,
increases fibrosis, and leads to
muscle contractile dysfunction. In
addition, TGFβ upregulates the
expression of NADPH oxidase 4
(Nox4), leading to oxidation of
ryanodine receptor (RyR1) which
causes calcium leak and muscle
weakness. Opportunities for
therapeutic intervention include
(1) blocking bone destruction
using bisphosphonates such as
zoledronic acid (ZA), (2) blocking
TGFβ activity with a neutralizing
antibody (1D11) or TGFβR1
kinase inhibitor (SD-208), (3)
blocking Nox4 activity
(GKT137831), or (4) reducing
RyR1 calcium leak using a Rycal
(S107)
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218 biochemical signature of RyR1 calcium leak was evident in
219 skeletal muscle samples taken from patients with breast cancer
220 that had bone metastases. This data was essential to validate
221 the clinical relevance of our pre-clinical mouse data.
222 TGFβ Leads to Increased Oxidative Stress
223 in the Skeletal Muscle
224 TGFβ has previously been directly implicated in muscle
225 weakness [28••] and we have shown that with osteolytic can-
226 cer in the bone; TGFβ signaling in muscle leads to an increase
227 in oxidative stress [42••]. In mice and humans with osteolytic
228 cancer in the bone, SMAD3 phosphorylation was increased,
229 which implicated a role for TGFβ signaling in skeletal muscle
230 weakness. To further investigate the role of the TGFβ signal-
231 ing pathway, we blocked TGFβ in mice with osteolytic breast
232 cancer in the bone with (1) SD-208 (TGFβ receptor I kinase
233 inhibitor) [45], (2) 1D11 (anti-TGFβ neutralizing antibody),
234 or (3) zoledronic acid (bisphosphonate that blocks the release
235 of TGFβ from the bone matrix) [40•]. All three therapeutic
236 interventions improved our measures of muscle function,
237 in vivo forelimb grip strength, and whole muscle contractility
238 of the EDL muscle. Importantly, anti-TGFβ monoclonal
239 (1D11) therapy in vivo confirms the specificity of TGFβ as
240 a mediator of skeletal muscle weakness whereas zoledronic
241 acid (to block bone resorption) confirms the bone as the
242 source of TGFβ.
243 In addition, therapeutic treatments that blocked TGFβ re-
244 lease or TGFβ signaling also reduced oxidation of yR1 and
245 also stabilized the interaction between calstabin1 and RyR1 in
246 a complex necessary for proper calcium handling in the skel-
247 etal muscle [4]. Due to the observed reduction in RyR1 oxi-
248 dation, we began to investigate the possible sources of skeletal
249 muscle oxidative stress. NADPH oxidase 4 (Nox4) is a con-
250 stitutively active enzyme that generates reactive oxygen spe-
251 cies (ROS); Nox4 is also a TGFβ target gene [46]. We found
252 that Nox4 expression increased in skeletal muscle from mice
253 with osteolytic cancer in the bone. Nox4 expression was re-
254 duced in mice treated with anti-TGFβ (SD-208 and ID11)
255 therapies or when mice were treated with zoledronic acid. In
256 cultured C2C12myotubes, TGFβwas found to increase Nox4
257 expression and increase RyR1 oxidation and leads to reduced
258 calstabin1-RyR1 binding. Silencing Nox4 reduced RyR1 ox-
259 idation and prevented the dissociation of calstabin1 from the
260 RyR1 complex. Interestingly, TGFβ also caused an increase
261 in the direct interaction between Nox4 and RyR1 in vitro. This
262 effect was recapitulated in the skeletal muscle from mice and
263 humans with osteolytic cancer in the bone. Finally, a Nox4
264 inhibitor (GKT137831 [47]) in mice, showed a significant
265 improvement in skeletal muscle function by whole muscle
266 contractility in mice with osteolytic cancer in the bone.
267 GKT137831 also caused a reduction in RyR1 oxidation in
268mice. Taken together, these data describe an important and
269novel TGFβ-Nox4-RyR1 axis that is responsible for skeletal
270muscle weakness in cases of osteolytic cancer in the bone
271[42••].
272Conclusions
273The functions of bone and muscle are tightly coupled in nor-
274mal physiology. Many recent studies have focused on the
275endocrine role of muscle and its interactions in bone-muscle
276crosstalk [4]. Osteolytic cancer in the bone significantly di-
277verges from normal bone physiology. Our recently published
278work shows the bone destruction driven by osteolytic cancer
279in the bone directly causes skeletal muscle weakness via mus-
280cle oxidative stress and calcium mishandling [4, 42••]. We
281have identified the novel TGFβ-Nox4-RyR1 axis as a critical
282mechanism that causes significant skeletal muscle weakness
283[42••]. These findings have large translational potential and
284clinical implications. Therapeutic treatments with agents that
285block RyR1 calcium leak, release of TGFβ from the bone,
286TGFβ signaling, or Nox4 activity all significantly improved
287muscle function in mice with osteolytic cancer in the bone
288[42••]. These findings are in addition to recent studies that
289have shown that TGFβ blockade, via long-term treatment
290with losartan, inhibited muscle destruction and promoted re-
291generation in the mdx mouse model of Duchenne muscular
292dystrophy [48]. It has also been shown that TGFβ blockade,
293using suramin, prevented exercise-induced skeletal muscle
294damage in mdx mice [49].
295New therapeutic targets for the debilitating complications
296of skeletal muscle weakness in cancer and other myopathies
297are needed. Studies that demonstrate new and novel mecha-
298nisms of bone-muscle crosstalk and identification and charac-
299terization of more factors that influence bone-muscle commu-
300nication will make a dramatic impact on possible therapeutic
301targets. These studies will lead to therapeutics to treat muscle
302weakness in cancer, as well as other bone diseases, and even
303aging.
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